Lakewood-Amedex Biotherapeutics, Inc. LABT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.35M | -4.23M | -3.85M | -3.96M | -- |
| Total Depreciation and Amortization | 121.60K | 120.80K | 120.00K | 119.20K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.79M | 1.35M | 1.35M | 1.37M | -- |
| Change in Net Operating Assets | -52.30K | 874.30K | 429.50K | 209.20K | -- |
| Cash from Operations | -3.49M | -1.89M | -1.94M | -2.26M | -- |
| Capital Expenditure | -- | -- | -- | 0.00 | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.00M | -- | -- | 841.00K | -- |
| Cash from Investing | -2.00M | -- | -- | 841.00K | -- |
| Total Debt Issued | 198.20K | 1.43M | 1.50M | 1.50M | -- |
| Total Debt Repaid | -198.20K | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | -- |
| Issuance of Preferred Stock | 6.80M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.80M | 1.43M | 1.50M | 1.50M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.32M | -465.30K | -444.70K | 80.10K | -- |